Results 91 to 100 of about 7,988 (196)

Countering immunotoxin immunogenicity [PDF]

open access: yesBritish Journal of Cancer, 2016
The entry of antibody-based drugs into mainstream medicine has provided the oncologist with new therapeutic tools that have begun to transform the treatment of cancer (Scott et al, 2012; Lee et al, 2013). Toxicity profiles and cell killing mechanism(s) exhibited by antibody and small-molecule cytotoxic therapies are largely non-overlapping, thus ...
openaire   +2 more sources

Macrophage-Targeted Therapy: CD64-Based Immunotoxins for Treatment of Chronic Inflammatory Diseases

open access: yesToxins, 2012
Diseases caused by chronic inflammation (e.g., arthritis, multiple sclerosis and diabetic ulcers) are multicausal, thus making treatment difficult and inefficient. Due to the age-associated nature of most of these disorders and the demographic transition
Theo Thepen   +4 more
doaj   +1 more source

Mycoflora and Aflatoxin Contamination of Some Foodstuffs [PDF]

open access: yes, 2013
Analysis was made of the mycoflora and aflatoxin contamination of Rice (Oryza sativa), Beans (Phaseolus vulgaris), Corn (Zea mays), and Groundnut (Arachis hypogaea) sold in four different markets in Sango-Ota, Ogun state, Nigeria.
Olarewaju, S.A., Oranusi, S. U.
core  

SS1P Immunotoxin Induces Markers of Immunogenic Cell Death and Enhances the Effect of the CTLA-4 Blockade in AE17M Mouse Mesothelioma Tumors

open access: yesToxins, 2018
SS1P is an anti-mesothelin immunotoxin composed of a targeting antibody fragment genetically fused to a truncated fragment of Pseudomonas exotoxin A. Delayed responses reported in mesothelioma patients receiving SS1P suggest that anti-tumor immunity is ...
Yasmin Leshem   +4 more
doaj   +1 more source

T-Cell Receptor-Like Antibodies: Targeting the Intracellular Proteome Therapeutic Potential and Clinical Applications

open access: yesAntibodies, 2013
Major histocompatibility complex (MHC) class I molecules are key in the immune response against malignant cells by shaping the T-cell repertoire and presenting peptides from endogenous antigens to CD8+ cytotoxic T cells.
Maya Cohen, Yoram Reiter
doaj   +1 more source

A case of accidental Ricin poisoning [PDF]

open access: yes, 2004
A case report of accidental, mild ricin poisoning by ingestion of ten Castor beans by a 70 year old man. The clinical presentation is followed by a discussion about the toxicity of ricin, its use and misuse and the contrast between the toxicity of pure ...
Cachia, Mario J., Despott, Edward
core  

Nanotechnology and cancer [PDF]

open access: yes, 2008
The biological picture of cancer is rapidly advancing from models built from phenomenological descriptions to network models derived from systems biology, which can capture the evolving pathophysiology of the disease at the molecular level.
Davis, Mark E., Heath, James R.
core   +2 more sources

Efficacy of Anti-Cancer Immune Responses Elicited Using Tumor-Targeted IL-2 Cytokine and Its Derivatives in Combined Preclinical Therapies

open access: yesVaccines
Effective cancer therapies must address the tumor microenvironment (TME), a complex network of tumor cells and stromal components, including endothelial, immune, and mesenchymal cells. Durable outcomes require targeting both tumor cells and the TME while
Sahar Balkhi   +5 more
doaj   +1 more source

Ricin: An Ancient Story for a Timeless Plant Toxin

open access: yesToxins, 2019
The castor plant (Ricinus communis L.) has been known since time immemorial in traditional medicine in the pharmacopeia of Mediterranean and eastern ancient cultures. Moreover, it is still used in folk medicine worldwide.
Letizia Polito   +4 more
doaj   +1 more source

A deimmunised form of the ribotoxin, α-sarcin, lacking CD4+ T cell epitopes and its use as an immunotoxin warhead [PDF]

open access: yes, 2016
Fungal ribotoxins that block protein synthesis can be useful warheads in the context of a targeted immunotoxin. α-Sarcin is a small (17 kDa) fungal ribonuclease produced by Aspergillus giganteus that functions by catalytically cleaving a single ...
Arron R. Hearn   +20 more
core   +1 more source

Home - About - Disclaimer - Privacy